Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 270-171-6 | CAS number: 68412-15-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
A NOAEL for systemic toxicity of 1000 mg/kg bw/day was established for Octadecanoic Acid, reaction products with triethylenetetramine based on information from an OECD 422 guideline study.
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017-08-09 to 2017-11-20
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- 29 July 2016
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source:
Envigo Netherlands, Kreuzelweg 53, 5961 NM Horst, Netherlands
- Females nulliparous and non-pregnant: yes
- Age at study initiation:
7 to 8 weeks old
- Weight at study initiation:
200 to 225 g for males and 175 to 200 g for females
- Fasting period before study: no
- Housing: From arrival to mating, animals were housed up to 5 of one sex to a cage, in polysulfone solid bottomed cages measuring 59.5×38×20 cm.
During mating, animals were housed one male to one female in clear polysulfone cages measuring 42.5×26.6×18.5 cm with a stainless steel mesh lid and floor.
After mating, the males were re-caged as they were before mating.
The femaleswere transferred to individual solid bottomed cages (measuring 42.5×26.6×18.5 cm) for the gestation period, birth and lactation.
- Diet (e.g. ad libitum):
ad libitum, A commercially available laboratory rodent diet (4 RF 21,Mucedola S.r.l., Via G. Galilei, 4, 20019, SettimoMilanese (MI), Italy)
- Water (e.g. ad libitum):
ad libitum to each cage via water bottles
- Acclimation period:
An acclimatisation period of approximately 3 weeks was allowed before the start of treatment,
during which time the health status of the animals was assessed by thorough observations.
ENVIRONMENTAL CONDITIONS
- Temperature (°C):
22°C ± 2°C
- Humidity (%):
55% ± 15%,
- Air changes (per hr):
15 to 20 air changes per hour
- Photoperiod (hrs dark / hrs light):
artificial light for 12 hours - Route of administration:
- oral: gavage
- Details on route of administration:
- The test item was administered orally by gavage at a dose volume of 10mL/kg body weight.
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The required amount of Octadecanoic Acid, reaction products with triethylenetetramine was suspended in the vehicle. The formulations were prepared daily (concentrations of 10, 30 and 100 mg/mL). Concentrations were calculated and expressed in terms of test item as supplied.
VEHICLE
- Justification for use and choice of vehicle (if other than water): standard vehicle
- Concentration in vehicle: The formulations were prepared daily (concentrations of 10, 30 and 100 mg/mL) in 0.5% aqueous solution of carboxymethylcellulose
- Amount of vehicle (if gavage): 10 mL/ kg - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The proposed formulation procedure for the test item was checked in the range from 10 to 100 mg/mL by chemical analysis (concentration and homogeneity) to confirm that the method was suitable.
Final results for all levels were within the acceptability limits for concentration (85-115%) and homogeneity (CV< 10%). - Duration of treatment / exposure:
- Females of the main groups were treated for 2 weeks prior to pairing, during pairing and throughout the gestation and lactation periods until Day 13 post partum, for a total of 42 to 64 days.
Females of the recovery groups were treated for a total of 56 days.
Males of the main groups were treated for 2 weeks prior to pairing and during pairing with females until the day before necropsy, for a total of 30/31 days.
Males of the recovery group were treated for a total of 28 days. - Frequency of treatment:
- once a day, 7 days a week
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Each main group comprised 10 male and 10 female rats (Groups 1 to 4).
Control and high dose level included 5 additional animals per sex to be sacrificed after 4 weeks of recovery (Groups 5 and 6). - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
Dose levels have been selectedbased on information from a preliminary study.
- Rationale for animal assignment:
The rats were allocated to the groups by computerised stratified randomisation to give approximately equal initial group mean body weights.
- Post-exposure recovery period in satellite groups: recovery from any treatment-related effects during a period of 4 weeks. - Positive control:
- not applicable
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule:
Animals were checked twice daily for mortality. Once before commencement of treatment and at least once daily during the study, each animal was observed and any clinical signs recorded.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule:
Once before commencement of treatment and at least once a week thereafter, each animal was given a detailed clinical examination.
BODY WEIGHT: Yes
- Time schedule for examinations: Males were weighed weekly from allocation to termination. Females were weighed weekly
from allocation to positive identification of mating and on Days 0, 7, 14 and 20 post coitum.
Dams were also weighed on Days 1, 4, 7, 13 post partum and just before necropsy.
Recovery groups: Each animal was weighed on the day of allocation to treatment groups, on the day that treatment commenced, weekly thereafter and just prior to necropsy.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: no feeding study
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: no feeding study
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: not applicable
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): not applicable
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at sacrificial procedure
- Anaesthetic used for blood collection: Yes; under isofluorane anaesthesia
- Animals fasted: Yes; under condition of food deprivation
- How many animals:
5 males and 5 females randomly selected from each main group
At the end of the recovery period, blood samples were also taken from all surviving animals of the recovery groups
- Parameters checked in table [No.1] were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at sacrificial procedure
- Anaesthetic used for blood collection: Yes; under isofluorane anaesthesia
- Animals fasted: Yes; under condition of food deprivation
- How many animals:
5 males and 5 females randomly selected from each main group
At the end of the recovery period, blood samples were also taken from all surviving animals of the recovery groups
- Parameters checked in table [No.1] were examined.
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: Yes
-- Time schedule:
Once before commencement of treatment and at least once a week thereafter, each animal was given a detailed clinical examination.
- Dose groups that were examined:
5/10 animals of the main groups selected randomly and in all animals of the recovery groups
Once duringWeek 4 of recovery, the MA was also performed in all recovery animals.
- Battery of functions tested: sensory activity / grip strength / motor activity
IMMUNOLOGY: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
The clinical history of the adult animals was studied and a detailed post mortem examination was conducted (including examination of the external surface and orifices).
Changes were noted, the requisite organs weighed (Table 2)(excluding animals sacrificed for humane reasons or found dead) and the required tissue samples preserved in fixative and processed for histopathological examination.
HISTOPATHOLOGY: Yes
Samples of all the tissues listed table 2 were fixed and preserved in 10% neutral buffered formalin (except eyes, optic nerves and Harderian glands, testes and epididymides which were fixed in modified Davidson’s fluid and preserved in 70% ethyl alcohol). - Statistics:
- Standard deviations were calculated as appropriate. For continuous variables the significance of the differences amongst group means was assessed by Dunnett’s test or a modified t test, depending on the homogeneity of data.
The non-parametric Kruskal-Wallis analysis of variance was used for the other parameters. Intergroup differences between the control and treated groups were assessed by the non-parametric version of theWilliams test.
The mean values, standard deviations and statistical analysis were calculated from actual values in the computer without rounding off.
Statistical analysis of histopathological findings was carried out by means of the non-parametric Kolmogorov-Smirnov test if ‘n’ was more than 5. - Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical signs of toxicological relevance were observed in males and females of main and recovery groups.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One low dose female was sacrificed for humane reasons on Day 23 post coitum for difficulty in parturition.
Pallor, decreased activity and piloerection were observed in this animal prior to sacrifice.
No treatment-related changes were observed after gross and histopathology evaluation. - Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No difference in body weights was recorded in animals of both sexes compared to the control group, throughout the study.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No effects on food consumption were observed in either males or females of main and recovery groups.
- Food efficiency:
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Slight lymphopenia was recorded in some females dosed at 300 and 1000mg/kg/day. However, due to the absence of dose-relation, these findings cannot be conclusively attributed to treatment.
Recovery phase (recovery phase animals): Lymphopenia and monocytopenia were still observed in females dosed at 1000mg/kg/day.
Coagulation: Dosing phase; no changes of toxicological relevance were observed. - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Dosing phase
Triglycerides were decreased in a number of animals of all treated groups, with no doserelation.
In addition, glucose was increased in males receiving 1000mg/kg/day and in some females from all treated groups, with no dose-relation.
Recovery phase
Triglycerides showed complete reversibility in animals of both sexes. In males, glucose was comparable with controls, even though data were similar to those recorded at the end of treatment. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Observation of animals at removal from the cage and in an open arena did not reveal changes attributable to the test item.
No treatment-related alterations in motor activity, grip strength and sensory reactivity to stimuli were observed in any treatment group at the examination performed at the end of treatment. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No treatment-related changes were observed in absolute and relative organ weight in all treatment groups of both sexes, when compared to the concurrent control data.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Gross pathology examination revealed no treatment-related changes.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- Histopathology evaluation revealed no treatment-related changes. Inparticular, no treatmentrelated findings were noted in the thyroid gland of all males and females of all main groups, when compared to their controls.
In addition seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and no alterations were noted. - Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- Histopathology evaluation revealed no treatment-related changes.
- Other effects:
- no effects observed
- Description (incidence and severity):
- Thyroid hormone determination:
Parental animals
No changes of toxicological relevance were observed at the end of dosing and recovery phases in parental males and females from main and recovery phase groups. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no treatment related effects observed
- Key result
- Critical effects observed:
- no
- Conclusions:
- Based on the results of the present study, the NOAEL for general toxicity was considered to be 1000 mg/kg/day for both males and females.
- Executive summary:
In a Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening study according to OECD guideline 422, Octadecanoic Acid, reaction products with triethylenetetramine was administered to 10 Sprague-Dawley rats /sex/ at dose levels of 0, 100, 300 and 1000 mg/kg bw/day by gavage.
Males of the main groups were treated for 2 weeks prior to pairing and during pairing with females until the day before necropsy, for a total of 30/31 days. Females of the main groups were treated for 2 weeks prior to pairing, during pairing and throughout the gestation and lactation periods until Day 13 post partum, for a total of 42 to 64 days.
Additionally a recovery group was included (5 rats/sex) for control and high dose with a 4 week treatment-free period in order to assess any delayed toxicity or recovery from any adverse effects observed during the dosing phase. Males of the recovery group were treated for a total of 28 days and killed after 4 weeks of recovery period. Females of the recovery groups were treated for a total of 56 days. The females were sacrificed after 4 weeks of recovery period.
One low dose female was sacrificed for humane reasons on Day 23 post coitum for difficulty in parturition. Pallor, decreased activity and piloerection were observed in this animal prior to sacrifice. No treatment-related changes were observed after gross and histopathology evaluation.
No clinical signs of toxicological relevance were observed in males and females of main and recovery groups.
No treatment-related alterations in motor activity, grip strength and sensory reactivity to stimuli were observed in any treatment group at the examination performed at the end of treatment.
No difference in body weights was recorded in animals of both sexes compared to the control group, throughout the study.
No effects on food consumption were observed in either males or females of main and recovery groups.
In main phase animals slight lymphopenia was recorded in some females dosed at 300 and 1000 mg/kg/day. However, due to the absence of dose-relation, these findings cannot be conclusively attributed to treatment. In recovery phase animals Lymphopenia and monocytopenia were still observed in females dosed at 1000 mg/kg/day. No changes of toxicological relevance were observed for coagulation parameters.
Triglycerides were decreased in a number of animals of all treated groups during dosing phase, with no dose relation. In addition, glucose was increased in males receiving 1000 mg/kg/day and in some females from all treated groups, with no dose-relation. Triglycerides showed complete reversibility in recovery animals of both sexes. In males of recovery group, glucose was comparable with controls, even though data were similar to those recorded at the end of treatment.
Terminal body weight of treated animals of the three main groups, as well as the high dose recovery group was comparable to the control group. No treatment-related changes were observed in absolute and relative organ weight in all treatment groups of both sexes, when compared to the concurrent control data.
Gross pathology examination revealed no treatment-related changes. Histopathology evaluation revealed no treatment-related changes. In particular, no treatment related findings were noted in the thyroid gland of all males and females of all main groups and of one male and one female pup of all dams on Day 14 post partum, when compared to their controls. In addition seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and no alterations were noted.
Conclusion
No treatment-related effects indicating systemic toxicity were observed in male or female animals from main and recovery groups at any of the dose levels investigated (100, 300 and 1000 mg/kg/day).
Based on the results of the present study, the NOAEL (No Observed Adverse Effect Level) for general toxicity was considered to be 1000 mg/kg/day for males and females.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- OECD 422 Guideline with GLP
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In a Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening study according to OECD guideline 422, Octadecanoic Acid, reaction products with triethylenetetramine was administered to 10 Sprague-Dawley rats /sex/ at dose levels of 0, 100, 300 and 1000 mg/kg bw/day by gavage.
Males of the main groups were treated for 2 weeks prior to pairing and during pairing with females until the day before necropsy, for a total of 30/31 days. Females of the main groups were treated for 2 weeks prior to pairing, during pairing and throughout the gestation and lactation periods until Day 13 post partum, for a total of 42 to 64 days.
Additionally a recovery group was included (5 rats/sex) for control and high dose with a 4 week treatment-free period in order to assess any delayed toxicity or recovery from any adverse effects observed during the dosing phase. Males of the recovery group were treated for a total of 28 days and killed after 4 weeks of recovery period. Females of the recovery groups were treated for a total of 56 days. The females were sacrificed after 4 weeks of recovery period.
One low dose female was sacrificed for humane reasons on Day 23 post coitum for difficulty in parturition. Pallor, decreased activity and piloerection were observed in this animal prior to sacrifice. No treatment-related changes were observed after gross and histopathology evaluation.
No clinical signs of toxicological relevance were observed in males and females of main and recovery groups.
No treatment-related alterations in motor activity, grip strength and sensory reactivity to stimuli were observed in any treatment group at the examination performed at the end of treatment.
No difference in body weights was recorded in animals of both sexes compared to the control group, throughout the study.
No effects on food consumption were observed in either males or females of main and recovery groups.
In main phase animals slight lymphopenia was recorded in some females dosed at 300 and 1000 mg/kg/day. However, due to the absence of dose-relation, these findings cannot be conclusively attributed to treatment. In recovery phase animals Lymphopenia and monocytopenia were still observed in females dosed at 1000 mg/kg/day. No changes of toxicological relevance were observed for coagulation parameters.
Triglycerides were decreased in a number of animals of all treated groups during dosing phase, with no dose relation. In addition, glucose was increased in males receiving 1000 mg/kg/day and in some females from all treated groups, with no dose-relation. Triglycerides showed complete reversibility in recovery animals of both sexes. In males of recovery group, glucose was comparable with controls, even though data were similar to those recorded at the end of treatment.
Terminal body weight of treated animals of the three main groups, as well as the high dose recovery group was comparable to the control group. No treatment-related changes were observed in absolute and relative organ weight in all treatment groups of both sexes, when compared to the concurrent control data.
Gross pathology examination revealed no treatment-related changes. Histopathology evaluation revealed no treatment-related changes. In particular, no treatment related findings were noted in the thyroid gland of all males and females of all main groups and of one male and one female pup of all dams on Day 14 post partum, when compared to their controls. In addition seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and no alterations were noted.
Conclusion
No treatment-related effects indicating systemic toxicity were observed in male or female animals from main and recovery groups at any of the dose levels investigated (100, 300 and 1000 mg/kg/day).
Based on the results of the present study, the NOAEL (No Observed Adverse Effect Level) for general toxicity was considered to be 1000 mg/kg/day for males and females.
Justification for classification or non-classification
Repeated dose toxicity of Octadecanoic Acid, reaction products with triethylenetetramine was assessed based on data from a Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening study.
The no-observed-adverse-effect-level (NOAEL) for systemic toxicity was considered to be 1000 mg/kg/day, the highest tested dose.
Evaluating information from the sub-acute toxicity study a classification with STOT-RE according to GHS Regulation EC No 1272/2008 for Octadecanoic Acid, reaction products with triethylenetetramine is not warrant.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.